



Synthesis, Characterisation, biological activity and Docking studies of ternary metal complexes of Cu(II) and Co(II) with 4-chloro-2-(2-Hydroxy) Naphthylidene Amino Benzothiazole Schiff base and Glycine ligands

Jagadish Tota¹ and Satyanarayana Battu^{*1}

¹Department of chemistry, University College of Science Osmania University Hyderabad, Telangana, India.

Email: jagadish.tota123@gmail.com

Abstract

The ternary complexes of Cu(II), Co(II) containing 4-chloro-(2-hydroxy)Naphthylidene aminobenzothiazole Schiff base and Glycine ligand were synthesised. These compounds were characterised by elemental analysis, FT-IR, UV-Vis, mass, TGA, molar conductance and SEM. From the electronic spectra and magnetic moment values the geometry of the complexes was determined. TGA data confirmed that there are no coordinated water molecules in the complexes. The binding mode of the Schiff base ligand to metal ions through azomethine nitrogen, oxygen of aldehyde and N, O donors of the glycine ligand was confirmed through the absorption bands appeared in the IR spectrum. Anticancer activity of the compounds revealed that Schiff base ligand and its Cu(II), Co(II) complexes have shown greater activity against the HeLa and MCF-7 cell lines. The complete cleavage of CT-DNA occurred with the Cu(II), Co(II) ternary complexes. The In vitro antimicrobial assessment of the Schiff base and its complexes have displayed that complexes have shown more activity than its free ligand. Docking studies were carried out on ligand to illustrate binding mode of ligand in to different active sites which are Pencillin binding protein 4 of *Staphylococcus aureus*, Penicillin Binding Protein 4 (dabB) of *E.coli* and *Homo sapiens* cyclin dependent kinase.

Keywords: Ternary metal complexes, IR, SEM, Antibacterial, DNA cleavage anticancer activity.

References

1. Abd El-halim, H. F., Omar, M. M., & Mohamed G. G. (2011) Spectrochim. Acta A, 78, 36.
2. Arun Pareek et al., (2010) Scholars Research Library, Der Pharma Chemica, 2(5),281-293.
3. Bensimon, G., Lacomblez, L., & Meiningier, V. (1994). New Engl. J. Med. 330, 585.
4. Carole Di Giorgio et al., (2002). Antimicrobial Agents and Chemotherapy. 46, 2588–2594.
5. Clark, M. J. (2003) Coord. Chem. Rev, 236, 209.
6. Dyson, J., & Sava G. (2006). Dalton Trans, 1929.
7. Emara, A. A. A. et al., (2010). Spectrochim. Acta A. 77, 117–125.
8. Filomena Corbo et al., (2013). European Journal of Medicinal Chemistry. 64, 357 – 364.
9. Foscolos, G., Tsatsas, G., Champagnac, A., & Pommier, M. (1977). Ann. Pharm. Fr. 35, 295.
10. Geary, W. J. Et al., (1971). Coord. Chem. Rev. 7, 81–122.
11. Galanski, M., Jakupc, M. A., & Keppler B. K. (2005). Curr. Med.Chem. 12, 2075.
12. Hays, S. J., Rice, M. J., Ortwine, D. F., Johnson, G., Schwartz, R. D., Boyd, D. K., Copeland, L. F., Vartanian, M. G., & Boxer, P. A., (1994). J. Pharm. Sci. 83, 1425.
13. He, Y., Benz, A., Fu, T., Wang, M., Covey, D. F., Zorumski, C. F., & Mennick, S.(2002) Neuropharmacology 42, 199.
14. Himaja, M. et al., (2011). International research journal of pharmacy. 2(1), 114-117.
15. Jimonet, P., Audiau, F., Barreau, M., Blanchard, J. C., Boireau, A., Y. Bour, Y., Coleno, M. A., Doble, A., Doerflinger, G., Huu, C. D., Donat, M. H., Duchesne, J. M., Ganil, P., Gueremy, C., Honore, E., Just, B., Kerphirique, R., Gontier, S., Hubert, P., Laduron, P. M., Le Blevec, J., Meunier, M., Miquet, J. M., Nemecek, C., Pasquet, M., Piot, O., Pratt, J., Rataud, J., Rebaud, M., Stutzmann, J. M., & Mignani, S.(1999). J. Med. Chem. 42, 2828.
16. Joseph, J., Nagashri, K., & Janaki, G. B. (2012). Eur. J. Med. Chem. 49,151–163.
17. Kuntal Hazra et al., (2011). Der Chemica Sinica.2(2),149-157.
18. Lever A. B. P. Et al., (1968). *Inorganic Electronic Spectroscopy*, second ed., Elsevier, New York.
19. Massari, S., Daelemans, D., Barreca, M. L., Knezevich, A., Sabatini, S., Cecchetti, V., Marcello, A., Panneccouque, C., & Tabarrini, O. (2010). J. Med. Chem. 53, 641.
20. Maurya, R. C., Rajput, S., "Oxovanadium (IV) complexes of bioinorganic and medicinal relevance: synthesis, characterization and 3D molecular modeling and analysis of some oxovanadium (IV) complexes involving the O, N-donor environment of pyrazolone-based sulfa drug Schiff bases."(2004). Journal of Molecular Structure. vol. 687, pp. 35.
21. (a)McDonnell, M. E., Vera, M. D., Blass, B. E., Pelletier, J. C., King, R. C., Fernandez-Metzler, C., Smith, G. R., Wrobel, J., Chen, S., Wall, B. A., & Reitz, A. B. Bioorg. Med. Chem. 20, 5642. (b) Cheah, B. C., Vucic, S., Krishnan, A. V., & Kiernan, M. C.(2010). Curr. Med. Chem.17, 1942.
22. Messori, L., Casini, A., Vullo, D., Haroutiunian, S.G., Dalian, E.B., & Orioli P. (2000). Inorg. Chim. Acta. 303,283.
23. Mohammad Shahar Yar et al., (2009) Acta Poloniae Pharmaceutical n Drug Research.66 387-392.
24. Mona A., & Mahran et al., (2007). Molecules. 12, 622-633.
25. Muttu, C. T. et al., (2010). International journal of research in ayurveda & pharmacy. 1(2), 522 – 528.
26. Nadeem Siddiqui et al., (2009). Acta Chim. Slov. 56, 462–469.
27. Navin Patel, B. et al., (2011). Journal of Enzyme Inhibition and Medicinal Chemistry. 26(4), 527–534.
28. Paget, C. J., Kisner, K., Stone, R. L., & Delong, D. C. (1969) J. Med. Chem.12, 1016.
29. Patel & Shaikh (2010). Journal of Sciences, Islamic Republic of Iran. 21(2)121-129.
30. Pratiwel, G., Pitie, M., Bernadou, J., & Meunier, B. (1991). Angew. Chem. Int. Ed. Eng. 30, 702–704.
31. Priya, N. P., Arunachalam, S., Manimaran, A., Muthupriya, D.,& Jayabalakrishnan C. (2009). Spectrochim. Acta A. 72, 6706.
32. Rosenberg, B., VanCamp, L., Trosko J. E.,& Mansour V. H. (1969). Nature. 222, 385.



33. Ravooft, T. B. S. A., Crouse, K. A., Tahir, M. I. M., How, F. N. F., Rosli R., & Watkins D. J. (2010). *Trans. Met. Chem.*, 35, 871.
34. Racane, L. et al., (2012). *European Journal of Medicinal Chemistry.* 55,108e116.
35. Ramesh, R., & Sivagamasundari, M. (2003). *Synth. React. Inorg. Met-Org. Chem.* 33, 899.
36. Sawhney, S. N., Arora, S. K., Singh, J. V., Bansal, O. P., & Singh, S. P. (1978). *Indian J. Chem.* 16B, 605.
37. Sharma, R. K., Singh R. V. et al. (1980). *Tandon, Inorg. Nucl. Chem.* 42, 1382.
38. Shirke Bobade, V. G., Bhamaria, R. P., Khadse, B. G., & Sengupta, S. R. (1990). *Indian Drugs.* 27(6), 350.
39. Suter, H., & Zutter H. (1967) *Helv. Chim. Acta.*50,1084.
40. (a) Van Heusden, J., Van Ginckel, R., Bruwiere, H., Moelans, P., Janssen, B., Floren, W., van der Leede, B. J., van Dun, J., Sanz, G., Venet, M., Dillen, L., Van Hove, C., Willemens, G., Janicot, M., & Wouters, W. (2002). *Br. J. Cancer.* 86, 605. (b) Aelterman, W., Lang, Y., Willemens, B., Vervest, I., Leurs, S., & De Knaep, F., (2001). *Org. Process Res. Dev.* 5, 467.
41. Verma, A. K. et al., (2014). *Indian J.Pharm.Biol.Res.* 2(3), 84-89.
42. Wong, E., & Giadomenico C. M. (1999). *Chem.Rev.* 99, 2451.
43. Wagenknecht, H. A., Stemp, E. D. A., & Barton J. K. (2000). *J. Am. Chem. Soc.* 122, 1.
44. Yin, H. D., Wang, Q. B., & Xue, S. C. (2004). *J. Organomet. Chem.* 689, 2480–2485.